Neurofibrillary tangles associated with Alzheimer's disease are composed mainly of paired helical filaments that are formed by the aggregation of abnormally phosphorylated microtubule-associated protein tau. 14-3-3, a highly conserved protein family that exists as seven isoforms and regulates diverse cellular processes is present in neurofibrillary tangles (Layfield, R., Fergusson,
Neurofibrillary tangles are one of the characteristic neuropathological lesions found in the brains of patients suffering from Alzheimer's disease (for a review, see Ref. 1) . The appearance of neurofibrillary tangles correlates spatially and temporally with Alzheimer's disease severity (2) . Neurofibrillary tangles are composed mostly of paired helical filaments (PHFs). 1 The principle component of PHFs is microtubule-associated protein tau (3, 4) . PHF-tau (tau associated with PHFs) is abnormally phosphorylated (contains more phosphate than normal tau), has reduced mobility on SDS-gel, and is incapable of performing its microtubule-related function (1, 3, 4) . Dephosphorylated PHF-tau has normal migration on SDS-gel and binds and promotes microtubule assembly in vitro (5, 6) . It is thought that abnormal phosphorylation causes loss of tau function, microtubule instability, PHF formation, and neurodegeneration. Abnormal tau phosphorylation has been suggested to be the key event in the development of Alzheimer's disease pathology (1, (3) (4) (5) (6) .
The abnormally phosphorylated PHF-tau contains 5-9 mol of phosphate/mol of tau, whereas tau isolated from normal brain contains 2-3 mol of phosphate/mol of tau (7) . In vivo normal adult tau is phosphorylated on Thr 181 , Ser
202
, Thr 231 , Ser 262 , and Ser 404 (all tau residues are numbered according to the longest isoform of human tau (8)) (9, 10 (9, 10) . PHF-tau on the other hand is phosphorylated on 19 sites (Table I) . Thus, PHF-tau is phosphorylated to a higher extent in terms of stoichiometry and sites. Aberrant activation of a tau-specific kinase(s) has been suggested to be involved in Alzheimer's disease pathogenesis (1, 3, 4, 9) . Therefore, much effort has focused on the identification of kinases that phosphorylate tau. Several kinases phosphorylate tau in vitro. These kinases include neuronal Cdc2-like protein kinase (NCLK), mitogen-activated protein kinase, glycogen synthase kinase 3␤, microtubule affinity-regulating kinase, phosphorylase kinase, protein kinase C, calmodulin-dependent protein kinase 2, casein kinase 1 and 2, and cAMP-dependent protein kinase (protein kinase A) (11) (12) (13) (14) (15) (16) (17) (18) (19) 400 , and Ser 404 contain (S/T)P motifs and are phosphorylated by the proline-directed kinases, NCLK, mitogenactivated protein kinase, and glycogen synthase kinase 3␤ (Table I). Ser 214 and Ser 409 are phosphorylated by protein kinase A (13), whereas Ser 262 is targeted by microtubule affinity-regulating kinase and phosphorylase kinase (16, 18) . Protein kinase C (14) , calmodulin-dependent protein kinase 2 (15) , casein kinase 1 (17) , and casein kinase 2 (19) phosphorylate tau on sites that do not appear to be phosphorylated in PHF-tau (4 413 , and Ser 422 are yet to be identified. Alternatively, tau may be phosphorylated by known kinase(s) in the presence of a tau-specific factor(s) that renders tau susceptible to phosphorylation on these sites.
14-3-3 is a family of highly conserved proteins that are ubiquitously expressed in various mammalian tissues (reviewed in Refs. 20 and 21) . There are nine isoforms of 14-3-3. These isoforms are ␣, ␤, ␥, ⑀, , , , ␦, and . The ␣ and ␦ isoforms are phosphorylated forms of ␤ and , whereas and are expressed only in T and epithelial cells, respectively. Originally, 14-3-3 was described as the activator of tyrosine and tryptophan hydroxylases (22) . Recent findings have shown that it is a cofactor of the bacterial Pseudomonas toxin (23) . Similarly, 14-3-3 binds to the Raf kinase and is required for Ras-Raf interaction (24 -26 ). 14-3-3 also interacts with protein kinase C, polyma middle T antigen, Bcr, P-I-3 kinase, Cdc25 phosphatase, insulin-like growth factor, and BAD (27) (28) (29) (30) (31) (32) (33) (34) (35) . Thus, 14-3-3 plays important roles in the regulation of diverse cellular processes such as signal transduction, cell cycle, apoptosis, exocytosis, and neurotransmitter biosynthesis (20 -35) . Recently, 14-3-3 was found to be associated with neurofibrillary tangles (36) . The role of 14-3-3 in PHF formation is not known. In this study, we have investigated the effect of 14-3-3 on tau phosphorylation. Herein we report that 14-3-3 is associated with tau in brain extract and stimulates tau phosphorylation. Our data suggest that 14-3-3 is an effector of tau phosphorylation.
EXPERIMENTAL PROCEDURES
Construction of 14-3-3 Plasmid-Nested polymerase chain reactions (PCR) were employed to produce human 14-3-3 cDNA. First, Pfu DNA polymerase (Stratagene) PCR (30 cycles) was carried out using the outer primer pair (5Ј-AAA AAG AAC ATC CAG TCA-3Ј and 5Ј-TAG CAA AAA TAA TGA AAG-3Ј) and a human cDNA library (CLONTECH) as template for 30 s at 95°C, 30 s at 51°C, and 2 min at 72°C. The PCR product was purified and used as template for the second PCR (25 cycles), which was performed as above using the inner primer pair (5Ј-GGA TCC ATG GAT AAA AAT GAG CTG GTT-3Ј and 5Ј-ACC AGT ATG TAG GCA GTT TTC-3Ј). After the second PCR, Taq polymerase was added to the reaction mixture, and the mixture was incubated at 72°C for 10 min. The final PCR product was isolated and ligated into a pGEM-T Easy Vector (Promega) and amplified. The DNA insert was excised from pGEM-T Easy Vector and ligated into the BamHI/EcoRI cloning sites of pGEX-6P-1 (Amersham Pharmacia Biotech) bacterial expression vector. The cDNA was confirmed by nucleotide sequencing.
Proteins and Peptides-Recombinant GST (glutathione S-transferase)-14-3-3 was purified from bacterial lysates. The overnight bacterial culture was diluted 20 fold in fresh medium and incubated at 37°C with vigorous shaking. After 2 h, isopropyl-␤-D-thiogalactoside was added to a final concentration of 1 mM to induce protein synthesis, and shaking continued for another 3 h. The bacterial culture was centrifuged, and the pellet was suspended in ice-cold lysis buffer (50 mM Tris-HCl (pH 7.4), 1 mM DTT, and 2 mM EDTA) containing 1% Tween 20, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml leupeptin, 1 g/ml pepstatin, and 1 g/ml aprotinin. The suspended bacterial pellet was sonicated for 30 s with a probe sonicator and centrifuged at 27,000 ϫ g for 30 min at 4°C. The supernatant was dialyzed against lysis buffer for 2 h and mixed with glutathione-agarose beads (Sigma) pre-equilibrated with lysis buffer containing 0.5% Nonidet P-40. The beads were shaken end-over-end for 3 h and packed in a glass column. The column was washed with a 20-column volume of lysis buffer and eluted with 10 mM reduced glutathione in lysis buffer. Eluted GST-14-3-3 was concentrated, dialyzed against lysis buffer, and stored frozen until used.
Tau and the tau deletion mutants Tau-(1-244), Tau-(245-369), and Tau-(245-441), containing tau residues 1-244, 245-369, and 245-441, respectively, were purified from respective bacterial lysates as described (37) . Each bacterial lysate was heated in a boiling water bath and centrifuged, and the supernatant was chromatographed through Q Sepharose followed by S-Sepharose columns as described (37) . NCLK was purified from fresh bovine brain extract (11) . Microtubules were purified from fresh bovine brain extract by three cycles of microtubule assembly and disassembly (37) . Tubulin was purified by phosphocellulose chromatography of microtubules (37) . Protein kinase A catalytic subunit and its peptide substrate kemptide were purchased from Sigma. NCLK peptide substrate (KTPKKAKKPKTPKKAKKL) was synthesized at the peptide synthetic facility of the University of Calgary.
Antibodies-Monoclonal anti-14-3-3⑀ was from Transduction Laboratories. Polyclonal antibodies against , ␥, and ␤ 14-3-3 isoforms were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Polyclonal antitau antibody that cross-reacts with phosphorylated and nonphosphorylated tau equally was raised at the antibody facility of the University of Calgary. Monoclonal antibody Tau-1 was from Roche Molecular Biochemicals. Monoclonal antibodies PHF-1 and 12E8 were gifts from Dr. Peter Davis (Albert Einstein College of Medicine, New York) and Ruth N. Motter (Athena Neurosciences), respectively.
GST Pull-down Assay-Glutathione-agarose beads (50 l each) coated with GST or GST-14-3-3 were mixed with 500 l of brain extract (ϳ1 mg/ml protein in buffer A (25 mM MOPS (pH 7.4), 50 mM ␤-glycerophosphate, 0.1 mM EDTA, 0.1 mM DTT, 15 mM MgCl 2 , 10 mM NaF, 1 g/ml leupeptin, 1 g/ml pepstatin, 1 mM PMSF, and 0.05% Nonidet P-40)) or tau solution (50 mM Tris-HCl (pH 7.4), 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.3% bovine serum albumin, and 20 g/ml indicated tau species) for 3 h at 4°C with end-over-end shaking. Beads were recovered by centrifugation and washed three times with 50 mM TrisHCl (pH 7.5), 0.5 M NaCl, 0.5% Nonidet P-40, and 1 mM DTT. Washed beads were mixed with 100 l of SDS-PAGE sample buffer, boiled, and centrifuged, and 10 l was immunoblotted with anti-tau antibody.
Phosphorylation Assay-Tau was mixed with GST or GST-14-3-3 in a vial and preincubated for 15 h at 4°C with end-over-end shaking. The concentrations of various components in the preincubation mixture were 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM DTT, 50 mM NaCl, 30 g/ml GST-14-3-3, and 0.2 mg/ml tau or 100 M peptide substrate. To 80 l of each preincubated mixture, 10 l of protein kinase A or NCLK was added. Phosphorylation was then initiated by adding 10 l of [␥-
32 P]ATP/Mg 2ϩ to each mixture. The final concentrations of various components in the assay were 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM DTT, 50 mM NaCl, 24 g/ml GST-14-3-3, 0.5 mM [␥-
32 P]ATP, 10 mM MgCl 2 , 100 units/ml NCLK or 10 g/ml protein kinase A, and 0.16 mg/ml tau or 80 M peptide substrate. To determine tau phosphorylation, aliquots (10 l each) were withdrawn after the indicated time point, mixed with an equal volume of SDS-PAGE sample buffer, and electrophoresed on a 10% SDS gel. The gel was stained and destained, and the tau band was sliced out from the gel and counted in a liquid scintillation counter to determine the amount of radioactivity incorporated into the protein. Peptide phosphorylation activities of NCLK and A kinase were measured by filter paper assay (16) .
Immunoprecipitation-Brain extract (ϳ0.5 ml) containing ϳ1 mg/ml protein in buffer A was precleared with 25 l of protein A-agarose beads (Sigma) pre-equilibrated in buffer A and divided into equal halves. To each half, 25 l of either preimmune serum or anti-tau antiserum was added, and both halves were shaken end-over-end at 4°C. After 4 h of shaking, 25 l of protein A-agarose beads pre-equilibrated in buffer A were added to each half, and shaking continued for another 1 h. Protein A-agarose beads were collected by centrifugation, washed five times with ice-cold buffer A, and immunoblotted using the indicated anti-14-3-3 antibody.
Other Methods-SDS-PAGE and immunoblotting were performed essentially as described (16) . Protein concentrations were determined by Bio-Rad protein assay using bovine serum albumin as the standard. NCLK concentration was based on units (11) . Concentrations of protein kinase A and kemptide were based on dry weights. Concentration of NCLK peptide substrate was determined by amino acid analysis.
RESULTS
Effect of 14-3-3 on Tau Phosphorylation-When tau was phosphorylated by protein kinase A in the presence of GST-14-3-3, tau phosphorylation progressively increased with an increasing GST-14-3-3 concentration (Fig. 1A) . At 30 g/ml GST-14-3-3 concentration, the maximum tau phosphorylation was observed. When a similar experiment was performed using GST in place of GST-14-3-3, tau phosphorylation remained unaffected (data not shown). These observations indicated that 14-3-3 stimulates tau phosphorylation by protein kinase A.
14-3-3 may stimulate tau phosphorylation by activating protein kinase A. Alternatively, 14-3-3 may make tau a better kinase substrate. To examine these possibilities, we tested the effect of GST-14-3-3 on kemptide phosphorylation by protein kinase A. As shown in Fig. 1B , GST-14-3-3 showed no effect on kemptide phosphorylation (open circles) but stimulated tau phosphorylation in a dose-dependent manner (solid circles). These data suggested that 14-3-3 is a tau effector (i.e. makes tau a better substrate of protein kinase A).
If 14-3-3 acts through tau, it should stimulate tau phosphorylation by other kinases as well. To test this, we examined the effect of GST-14-3-3 on tau phosphorylation by NCLK. GST-14-3-3 again stimulated tau phosphorylation and had no effect on the synthetic peptide substrate phosphorylation (Fig. 1C) . Control GST showed no effect on both tau or peptide phosphorylation by NCLK (data not shown). Based on these data, we concluded that 14-3-3 is a tau phosphorylation modulator. Fig. 1 , we preincubated tau with various GST-14-3-3 amounts for ϳ15 h before phosphorylation. To further examine 14-3-3-stimulated tau phosphorylation, we kept GST-14-3-3 concentration constant and preincubated tau and GST-14-3-3 mix-ture for different time points. Each preincubated tau species was phosphorylated by NCLK or protein kinase A. GST-14-3-3 displayed very little effect on tau phosphorylation by NCLK when tested without any preincubation. The stimulatory effect of GST-14-3-3 became apparent after ϳ2 h preincubation. At the ϳ10-h preincubation time point, the stimulatory effect peaked and remained constant during the next 24 h, the maximum time point tested (data not included). NCLK phosphorylation of control tau species preincubated with GST for various time points remained constant throughout the preincubation time points. Similarly, protein kinase A phosphorylation of tau preincubated with GST-14-3-3 increased with increasing preincubation time point, peaked at ϳ10 h preincubation time and then remained constant, whereas phosphorylation of tau species preincubated with GST was unaffected by preincubation time (data not shown). These observations indicated that 14-3-3 stimulates tau phosphorylation by protein kinase A or NCLK only when the tau-14-3-3 mixture is preincubated.
Effect of Preincubation Time on Tau Phosphorylation-In

14-3-3 Enhances Protein Kinase A Catalyzed Tau Phosphorylation on Ser
262/356 -Tau phosphorylated by several kinases displays a characteristic reduced mobility on SDS gels (13) (14) (15) (16) . Factors that affect tau phosphorylation may influence tau migration on SDS gel (38, 39) . To examine the effect of 14-3-3 in detail, we phosphorylated tau by protein kinase A in the presence of GST-14-3-3 and analyzed the products by SDS-PAGE followed by immunoblot analysis using an anti-tau antibody that cross-reacts equally with phosphorylated and nonphosphorylated tau. As observed previously (13, 38) , tau phosphorylation by protein kinase A in presence of buffer (data not shown) or GST ( Fig. 2A) displayed two bands. One band migrated with a mobility similar to nonphosphorylated tau, and the second band migrated more slowly than the first band. Surprisingly, tau phosphorylated by protein kinase A in the presence of GST-14-3-3 displayed an electrophoretic mobility pattern almost identical with the control tau phosphorylated in the presence of GST (Fig. 2A) . These data indicated that GST-14-3-3-stimulated tau phosphorylation does not affect tau migration on a SDS gel.
To gain further insight into 14-3-3-stimulated tau phosphorylation, we probed protein kinase A phosphorylated tau in the presence of GST-14-3-3 with three different phosphorylationsensitive monoclonal anti-tau antibodies: Tau-1, PHF-1, and 12E8. Tau-1 recognizes amino acid residues 189 -207 when all of the serines within this region are nonphosphorylated (40, 41) . PHF-1 and 12E8 recognize phosphorylated tau. The PHF-1 epitope is located within tau region 389 -402 (41, 42), whereas 12E8 was raised against a phosphorylated synthetic peptide derived from tau sequence 254 -266 (10). As shown in Fig. 2B , tau species phosphorylated by protein kinase A in the presence of GST or GST-14-3-3 cross-reacted with Tau-1 with almost equal intensities. Similarly, both tau species failed to immunoreact with PHF-1 (Fig. 2C) . Control tau phosphorylated by protein kinase A in the presence of buffer also cross-reacted with Tau-1 and was not recognized by PHF-1 (data not shown). These observations indicated that 14-3-3 does not influence the Tau-1 and PHF-1 epitopes of tau.
When probed with 12E8, tau species phosphorylated by pro- FIG. 1 . Effect of 14-3-3 on tau phosphorylation. Tau or the indicated peptide substrate was preincubated with the indicated concentration of GST-14-3-3, GST, or buffer for 15 h at 4°C and phosphorylated by protein kinase A or NCLK. Tau phosphorylation was carried out for 60 min and was monitored by either SDS-PAGE/autoradiography (A) or by slicing out the tau band from the SDS gel and counting the incorporated radioactivity into tau by a scintillation counter (B and C). Peptide phosphorylation was performed for 30 min and analyzed by filter paper assay (16) . A, autoradiography of tau phosphorylation by protein kinase A. Tau control incubated with all the components of the assay except protein kinase A is indicated as C. B, phosphorylation of tau or peptide by protein kinase A; C, phosphorylation of tau or synthetic peptide by NCLK. Values in A and B for each substrate are expressed as a percentage of the phosphorylation values of that substrate preincubated with buffer. GST displayed no effect on activities of both kinases against any substrate (data not shown).
FIG. 2.
Immunoblot analyses of tau phosphorylated by protein kinase A in the presence of 14-3-3 by using phosphorylationinsensitive and -sensitive anti-tau antibodies. Tau preincubated with GST or GST-14-3-3 for ϳ15 h was phosphorylated by protein kinase A for 60 min as in Fig. 1A . After phosphorylation, samples (10 l each) were immunoblotted with indicated anti-tau antibody. Anti-tau polyclonal antibody cross-reacts with both phosphorylated and nonphosphorylated tau. Tau-1 and PHF-1 monoclonal antibodies recognize nonphosphorylated and phosphorylated tau, respectively. For details, see "Results." tein kinase A in the presence of GST or GST-14-3-3 displayed immunoreactivity, and the band intensities increased with the increase in phosphorylation time (Fig. 3A) . However, tau phosphorylated in the presence of GST-14-3-3 became immunoreactive to 12E8 within 5 min of phosphorylation. The 12E8 epitope became apparent in tau phosphorylated in the presence of GST only after 30 min of phosphorylation. Densitometric quantitation of various bands in Fig. 3A indicated that at the 180-min time point, tau phosphorylated in the presence of GST-14-3-3 was ϳ15 times more immunoreactive to 12E8 than tau phosphorylated in presence of GST (Fig. 3B) . Tau phosphorylated by protein kinase A in the presence of buffer control displayed immunoreactivity against 12E8 very similar to tau phosphorylated by protein kinase A in presence of GST (data not shown). Based on these data and the specificity of 12E8 to recognize tau specifically phosphorylated on Ser 262 and/or Ser 356 (10), we concluded that 14-3-3 profoundly stimulates phosphorylation of tau residues Ser 262 /Ser 356 by protein kinase A. Figs. 1-3 suggested that 14-3-3 could be a tau phosphorylation modulator in brain. We therefore examined if 14-3-3 interacts with tau. We immunoprecipitated tau from fresh brain extract by using anti-tau antibody. The resulting anti-tau immune complex was immunoblotted using an anti-14-3-3 antibody. As shown in Fig. 4A, 14-3 -3 co-immunoprecipitated with tau. These data indicated that 14-3-3 is associated with tau in brain. To gain more evidence in favor of the above notion, we performed a GST pull-down assay. Glutathione-agarose beads coated with GST or GST-14-3-3 were mixed with brain extract, washed, and immunoblotted with anti-tau antibody. As expected, tau came down with GST-14-3-3 from brain extract but not with GST (Fig. 4B ).
14-3-3 Associates with Tau in Brain-Our data in
14-3-3 Directly Binds to Tau-In the brain, 14-3-3 may directly bind to tau. Alternatively, 14-3-3 may associate with tau via another biological molecule(s). To determine if 14-3-3 directly binds to tau, we performed a direct binding assay.
Glutathione-agarose beads coated with GST or GST-14-3-3 were mixed with purified recombinant tau and washed, and then tau bound to beads was detected by immunoblot analysis using an anti-tau antibody. Tau did not bind to GST but was associated with GST-14-3-3 (Fig. 5 ). These observations indicated that 14-3-3 directly binds to tau. To determine K a (the concentration of tau required for half-maximal binding), we performed a similar binding experiment, except concentration of tau in the assay was varied from 10 to 400 g/ml. The tau band intensities on the blot were quantitated by a Densitometer SI (Molecular Dynamics, Inc., Sunnyvale, CA), and the K a value was determined by the double reciprocal plot of the data using linear regression analysis. 14-3-3 bound to tau with a K a value 0.9 Ϯ 0.5 M (n ϭ 3) (data not shown).
Location of 14-3-3-Binding Region within Tau-The tau molecule contains three main functional domains: an N-terminal projection domain, a microtubule-binding repeat, and a C-terminal tail (1, 8) . The microtubule-binding region of the longest isoform of tau contains four microtubule-binding repeats (Fig. 6A) . To localize the 14-3-3 binding region within tau, we used three tau deletion mutants: Tau-(1-244), Tau-(245-369), and Tau-(245-441). Tau-(1-244) and Tau-(245-369) contain the projection domain and the microtubule-binding region, respectively. Tau-(245-441) contains the microtubulebinding region and the C-terminal tail. These mutants were purified from respective bacterial lysates, and their bindings with GST-14-3-3 were evaluated. GST-14-3-3 bound to wild type (Fig. 6B) but not with Tau-(1-244) (Fig. 6C) , indicating that tau does not bind to 14-3-3 through its projection domain. However, both Tau-(245-369) and Tau-(245-441) bound to GST-14-3-3 (Fig. 6, D and E) . Since Tau-(245-441) contains the microtubule-binding region and the C-terminal tail, whereas Tau-(245-369) contains only the microtubule-binding region, these data indicated that 14-3-3 binds to the microtubule-binding region of tau.
Tau Phosphorylation Is Not Required for 14-3-3-Tau Binding-14-3-3 usually interacts with phosphoproteins (21, 22).
We therefore investigated the effect of tau phosphorylation on tau-14-3-3 binding. Glutathione-agarose beads coated with 
FIG. 4.
Co-immunoprecipitation of 14-3-3 with tau from brain extract and GST pull-down assay. A, co-immunoprecipitation. Tau was immunoprecipitated from fresh bovine brain extract using anti-tau antibody. The anti-tau immune complex was immunoblotted with anti-14-3-3 antibody. B, GST pull-down assay. Glutathione-agarose beads coated with GST or GST-14-3-3 were mixed with fresh bovine brain extract, washed, and immunoblotted with anti-tau antibody.
14-3-3 were mixed with tau or phosphorylated tau. The beads were washed, and bound tau was detected by immunoblot analysis using an anti-tau antibody that cross-reacts with tau and phosphorylated tau with equal affinity. GST-14-3-3 bound to tau (Fig. 7A) as well as to phosphorylated tau (Fig. 7B ). These observations indicated that tau phosphorylation does not influence 14-3-3-tau binding.
To further demonstrate that tau phosphorylation is not required for 14-3-3-tau binding, we performed a GST pull-down assay. Glutathione-agarose beads coated with 14-3-3 were mixed with brain extract washed and analyzed by immunoblot analysis using the phosphorylation-sensitive anti-tau antibody Tau-1 that recognizes nonphosphorylated tau. As expected, tau bound to GST-14-3-3 intensely cross-reacted with Tau-1 (Fig. 7C ).
14-3-3 Associates with Microtubules-Microtubules in brain extract polymerize at 37°C in the presence of GTP/Mg 2ϩ . If incubated at 0°C, these polymerized microtubules depolymerize and become soluble. Microtubules are purified from brain extracts by two or three cycles of this temperature-induced polymerization and depolymerization. Proteins that bind to microtubules in vivo usually copurify with microtubules (43) .
Since a number of tau-binding proteins associate with microtubules (37, 44, 45) , we investigated the presence of 14-3-3 in microtubules. Microtubules were purified from fresh bovine brain extract by repeated cycles of temperature-induced polymerization and depolymerization. As shown in Fig. 8, 14-3-3 was present in supernatant (lane 2) and microtubule pellet (lane 3) during the first cycle. To determine if 14-3-3 in the microtubule pellet was microtubule-bound or nonspecifically trapped, the pellet was solubilized, centrifuged to remove insoluble aggregates, and subjected to second microtubule polymerization. Immunoblot analysis determined that 14-3-3 was present in the second microtubule pellet (Fig. 8, lane 5) . When the second microtubule pellet was subjected to a third polymerization/ depolymerization cycle, 14-3-3 was still present in the microtubule pellet and could not be washed out (lane 7). These observations indicate that 14-3-3 is tightly associated with microtubules.
Tubulin and 14-3-3 Compete for Tau Binding-Binding of 14-3-3 to the microtubule-binding region of tau (Fig. 6) suggested that tubulin and 14-3-3 might bind to tau in a mutually exclusive manner. To test this suggestion, we evaluated the effect of tubulin on GST-14-3-3-tau binding. Glutathione-agarose beads coated with GST or GST-14-3-3 were mixed with tau and various amounts of tubulin. The beads were washed, and bound tau was detected by immunoblot analysis using an anti-tau antibody. As shown in Fig. 9 , the presence of an increasing amount of tubulin in the binding mixture progressively decreased the amount of tau bound to GST-14-3-3 beads. When the amount of tubulin in the binding mixture reached ϳ2-fold molar excess than GST-14-3-3, no GST-14-3-3-bound tau was detected. These data indicated that tubulin blocks 14-3-3-tau binding.
Tau Binds to and ␤ Isoforms of 14-3-3-⑀, ␤, ␥, and 14-3-3 isoforms are highly expressed in mammalian brain (20, 21) . To   FIG. 5. 14-3-3 directly binds to tau. Glutathione-agarose beads coated with GST or GST-14-3-3 were mixed with tau, washed, and immunoblotted with anti-tau antibody.
FIG. 6.
Localization of 14-3-3 binding region within tau. Glutathione-agarose beads coated with GST or GST-14-3-3 were mixed with the indicated tau species, washed, and immunoblotted with antitau antibody. A, a schematic sketch of various tau species used in the assay. B-E, immunoblot analyses of samples representing full-length tau (WT), Tau-(1-244), Tau-(245-369), and Tau-(245-441), respectively.
FIG. 7. Effect of tau phosphorylation on 14-3-3-tau binding.
Glutathione-agarose beads coated with GST or GST-14-3-3 were mixed with tau, phosphorylated tau, or bovine brain extract. Beads were washed and immunoblotted with the indicated antibody. A-C show blots representing beads mixed with tau, phosphorylated tau, and brain extract, respectively. NCLK-phosphorylated tau used in B was prepared as described (11) .
examine if tau displays any isoform-specific interaction with 14-3-3, we immunoprecipitated tau from brain extract using anti-tau antibody. The anti-tau immune complex was analyzed by immunoblot analysis using various 14-3-3 isoform-specific antibodies. As shown in Fig. 10 , ␤ (A) and (D) 14-3-3 isoforms co-immunoprecipitated with tau from brain extract. However, ␥ (C) and ⑀ (B) isoforms, although abundantly present in brain extract, were undetectable in anti-tau immune complex. These data indicated that ␤ and but not ␥ or ⑀ 14-3-3 isoforms associate with tau. DISCUSSION 14-3-3 binds to a wide variety of proteins that include insulin-like growth factor 1 receptor (34), Raf (24 -26) , protein kinase C (27) , Bcr (29), Cb1 (30), P-I-3 kinase (32), Cdc25 phosphatase (31, 33) , and death agonist BAD (35). 14-3-3 also binds to Pseudomonas aeruginosa exoenzyme S (23) and to tyrosine and tryptophan hydroxylases (22) . By binding to these proteins, 14-3-3 regulates diverse cellular processes such as signal transduction, cell cycle, apoptosis, exocytosis, and neural function (20, 21 ).
14-3-3 is abundantly expressed in brain and co-immunoprecipitates with tau from fresh bovine brain extract (Fig. 4A) . Likewise, tau comes down with GST-14-3-3 from the brain extract in a GST pull-down assay (Fig. 4B) . In vitro 14-3-3 binds to tau (Fig. 5 ) and stimulates tau phosphorylation by protein kinase A and NCLK (Fig. 1) . Finally, 14-3-3 (this study) and tau (43) are associated with microtubules. These observations suggest that tau is also a 14-3-3 target in the brain.
14-3-3 has been suggested to bind and change the conformation of its target proteins (20, 21) . Observations along this model are stimulation of tryptophan and tyrosine hydroxylases (22) and P. aeruginosa exoenzyme S (23) activities by 14-3-3. We found that 14-3-3 also stimulates tau phosphorylation by protein kinase A and NCLK in a dose-dependent manner (Fig.  1) . When tau is replaced by respective synthetic peptide substrates, activities of both kinases become insensitive to 14-3-3. These observations indicate that 14-3-3 is a tau modulator. Furthermore, tau phosphorylation by protein kinase A in the absence of any effector displayed very poor immunoreactivity against 12E8. However, tau phosphorylated by protein kinase A in the presence of 14-3-3 under identical conditions intensely cross-reacted with 12E8 (Fig. 3) 14-3-3 preferentially binds to Ser-phosphorylated proteins (20, 21, 48) . By using bacterially expressed tau, we demonstrated that both tau and phosphorylated tau display 14-3-3 binding (Fig. 7) . Similarly, tau bound to GST-14-3-3 in a GST pull-down assay displays immunoreactivity to Tau-1 (Fig. 7C) , an anti-tau monoclonal antibody that recognizes nonphosphorylated tau (40) . Thus, tau is one of the few proteins that interact with 14-3-3 in a phosphorylation-independent manner. Other proteins that bind to 14-3-3 in the nonphosphorylated state are glycoprotein Ib␣ (49) and exoenzyme S of P. aeruginosa (50) . It should be mentioned here that ␣ synucleintau binding also does not require tau phosphorylation (47) .
Tau is a microtubule-associated protein, and its main function in neurons is to bind and stabilize microtubules (1, 43) . Phosphorylation of tau reduces tau's affinity for microtubules (13, 18) . Phosphorylation of tau thus regulates microtubule-tau interaction and microtubule dynamics (1, 42 are uniquely located within the microtubule-binding region of tau (Fig. 6A) . Phosphorylation of these sites is sufficient to detach tau from microtubules and has been suggested to play an important role in the regulation of tau-microtubule interaction and microtubule dynamics (16, 18 14-3-3 (Fig. 3) . Furthermore, 14-3-3 binds to tau in vitro (Fig.   FIG. 8. 14-3-3 is associated with microtubules. Microtubules were purified from fresh bovine brain extract through repeated cycles of microtubule assembly and disassembly. The supernatant (10 l) and pellet (10 g) from each cycle were analyzed by immunoblot analysis using anti-14-3-3 antibody. 5), co-immunoprecipitates with tau from brain extract (Fig.  4A) , and co-purifies with microtubules from brain extract through repeated cycles of microtubule assembly/disassembly (Fig. 8 ). These observations suggest that 14-3-3 regulates tau phosphorylation and microtubule dynamics in the brain.
Tau binds to microtubules through its microtubule-binding region. However, several proteins such as actin (51), calmodulin (52), phosphatase 2A (44), NCLK (37) , and ␣-synuclein (47) bind to the microtubule-binding region of tau. Using tau deletion mutants, we determined that 14-3-3 also binds to the microtubule-binding region of tau (Fig. 6 ). These observations are consistent with the notion that tau uses its microtubulebinding region for interaction not only with microtubules but with various other proteins as well (37) .
In Alzheimer's disease, tau becomes abnormally phosphorylated and aggregates into PHFs. Abnormal phosphorylation may prevent tau from performing its microtubule-related functions, causing cytoskeletal dysfunction and perhaps neurodegeneration. Aberrant activation of a tau-specific kinase was suggested to be involved in Alzheimer's disease pathogenesis (1, 3, 4, 9, 53) . Similarly, down-regulation of a tau-specific phosphatase in Alzheimer's disease brain was also suggested (54) . However, fetal tau, which is also hyperphosphorylated and shares many abnormal phosphorylation sites with PHFtau (Table I) , does not form PHFs, and PHF-like filaments can be reconstituted from nonphosphorylated tau in vitro (55) . Thus, it is yet to be resolved if in Alzheimer's disease brain abnormal phosphorylation causes tau aggregation. Similarly, it is still not clear whether accumulation of abnormally phosphorylated tau in Alzheimer's disease brain occurs due to aberrant activation/inactivation of tau-specific kinases/phosphatases and/or due to abnormally phosphorylated tau aggregate being resistant to phosphatases.
Layfield et al. (36) investigated the localization of 14-3-3 in postmortem Alzheimer's disease brains. They detected 14-3-3 immunostaining in neurofibrillary tangles in all of the cases examined. These observations indicate that 14-3-3 is tightly associated with neurofibrillary tangles and may have a role in Alzheimer's disease pathogenesis. Recently, protein kinase A has also been found to be associated with neurofibrillary tangles and was suggested to participate in abnormal tau phosphorylation occurring in Alzheimer's disease brain (56) . In this study, we showed that 14-3-3 stimulates tau phosphorylation on Ser (Table I) , and as discussed above phosphorylation on Ser 262 /Ser 356 is sufficient to block tau-microtubule interaction, causing microtubule instability (16, 18) . These observations suggest that 14-3-3 may be a tau-specific co-factor involved in the abnormal phosphorylation of tau during Alzheimer's disease development. It should also be noted that 14-3-3 induces oligomerization of its target proteins (57, 58) , and 14-3-3-bound proteins are resistant to phosphoprotein phosphatases (59) . It is possible that in addition to stimulating tau phosphorylation 14-3-3 may also cause tau aggregation and/or make abnormally phosphorylated tau refractory to phosphatases in the Alzheimer's disease brain.
This study emphasized the interaction of tau with the 14-3-3 isoform. However, among four isoforms we tested, and ␤ were present in anti-tau immune complex, whereas ␥ and ⑀ could not be detected. These observations indicate that tau interacts with and ␤ but not with ␥ and ⑀ 14-3-3 isoforms. 14-3-3 is a family of highly conserved proteins. In mammalian tissues, there are seven isoforms (20, 21) . These isoforms have very few conserved amino acid substitutions but display highly isoform-specific interactions with their target proteins. For example, while all isoforms can activate tryptophan hydroxylase (21) , only ␤ and isoforms associate with Raf (20, 21, 60) . Similarly, the ␦ isoform interacts more strongly with protein kinase C than the isoform (61) , and Bcr binds to the isoform (20, 29) . Since 14-3-3 forms homo-and heterodimers, it is thought that isoform-specific interaction of 14-3-3 with various proteins allows 14-3-3 heterodimers to function as scaffold proteins to mediate protein complex assembly (20, 21) . More studies will be required to elucidate the physiological significance of the interaction of tau with and ␤ 14-3-3 isoforms.
